Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Concurrent Chemoradiation With Consolidation Pembrolizumab for the Treatment of Inoperable or Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC): HCRN LUN14-179

NCT02343952 is registered in ClinicalTrials.gov with Nasser Hanna, M.D. as lead sponsor.

NCT NCT02343952
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02343952 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Concurrent Chemoradiation With Consolidation Pembrolizumab for the Treatment of Inoperable or Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC): HCRN LUN14-179
Lead sponsor
Nasser Hanna, M.D.
Phase
Phase 2
Overall status
Completed
Start date
March 9, 2015
Completion date
January 1, 2021
Enrollment
93 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, non-small-cell lung